Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00868439 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Patiromer in Heart Failure Patients

A Phase 2 study of Heart Failure and Hyperkalemia, sponsored by Relypsa.

Completed
Registry status
Phase 2
Development phase
120
Enrollment target
20
Study locations

NCT00868439 is a Phase 2 study of Heart Failure and Hyperkalemia that has completed, run by Relypsa. The registered enrollment target is 120 participants, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00868439, a Phase 2 study of Heart Failure and Hyperkalemia, has completed, sponsored by Relypsa.

COMPLETED
Registry status
Phase 2
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.

Conditions Studied

Heart Failure Hyperkalemia

Interventions

  • DRUG placebo
  • DRUG patiromer

Study Locations (20)

Other

  • Investigator Site 102 - Brno
  • Investigator Site 104 - Prague
  • Investigator Site 103 - Prague
  • Investigator Site 605 - Tbilisi
  • Investigator Site 602 - Tbilisi
  • Investigator Site 604 - Tbilisi
  • Investigator Site 603 - Tbilisi
  • Investigator Site 201 - Göttingen
  • Investigator Site 202 - Heidelberg
  • Investigator Site 305 - Warsaw
  • Investigator Site 409 - Barnaul

Florida

  • Investigator Site 029 - Miami
  • Investigator Site 031 - Port Charlotte

New York

  • Investigator Site 020 - Buffalo
  • Investigator Site 005 - Northport

Illinois

  • Investigator Site 009 - Peoria

Minnesota

  • Investigator Site 018 - Minneapolis

Ohio

  • Investigator Site 022 - Columbus

Texas

  • Investigator Site 001 - Dallas

Utah

  • Investigator Site 019 - Salt Lake City

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2009-04
Est. Completion 2009-12
Phase Phase 2

Sponsor

Relypsa

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00868439

The ClinicalTrials.gov registry entry for NCT00868439 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 397 other Heart Failure trials with a reported enrollment target (94% lower). The listed sponsor is Relypsa, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00868439 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Florida, New York.

Frequently Asked Questions

What is clinical trial NCT00868439 about?

NCT00868439 is a clinical study titled "Evaluation of Patiromer in Heart Failure Patients". The purpose of this study was to assess the effects of patiromer on serum potassium participants with heart failure. This study also assessed the safety and tolerability of patiromer in participants with heart failure.

What is the current status of trial NCT00868439?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2009-04. Estimated completion is 2009-12.

What conditions does trial NCT00868439 study?

This clinical trial studies the following conditions: Heart Failure, Hyperkalemia.

What interventions are being tested in trial NCT00868439?

The interventions under investigation include: placebo (DRUG), patiromer (DRUG).

Who is sponsoring clinical trial NCT00868439?

This trial is sponsored by Relypsa, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00868439 being conducted?

This trial has 20 study locations across Florida, Illinois, Minnesota, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure

All registered trials for this condition

Hyperkalemia

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.